 He was the founding director for the Delaware Valley Institute for Clinical and Translational Science.He has been an advocate for innovative research funding including being called to give testimony to the committee on appropriations for the United States Senate in 2009.In January 2019, Pestell was named vice chairman of CytoDyn, Inc., who acquired his prior company, ProstaGene, in November 2018.